U.S. Psychedelic Mushroom Products Market Size 2026 to 2035

The U.S. psychedelic mushroom products market size stood at USD 1.95 billion in 2025 and is expected to grow from USD 2.26 billion in 2026 to reach  approximately USD 8.46 billion by 2035, expanding at a CAGR of 15.8% from 2026 to 2035. Expanding decriminalization efforts and growing consumer shift toward natural, alternative treatments further support market expansion. Additionally, the surge in microdosing trends and the availability of convenient product formats through online channels are accelerating adoption.

Key Takeaways

• By product type, the psilocybin-infused products segment led the market with a 38% share in 2025.
• By product type, the microdosing products segment held a 22% market share in 2025 and is expected to grow at the 18.9% CAGR in the market during the forecast period.
• By application, the mental health treatment segment led the market with a 44% share in 2025 and is expected to grow at 17.8% CAGR in the market during the forecast period.
• By distribution channel, the online retail segment led the market with a 36% share in 2025 and is expected to grow at 18.2% CAGR in the U.S. psychedelic mushroom products market during the forecast period.
• By end user, the adults (25-45 years) segment led the market with a 42% share in 2025.
• By end user, the clinical patients segment held a 26% market share in 2025 and is expected to grow at 18.5% CAGR in the market during the forecast period.
• By dosage type, the microdose segment led the market with a 46% share in 2025 and is expected to grow at 18.6% CAGR in the market during the forecast period.
• By source, the natural mushrooms segment led the market with a 62% share in 2025.
• By source, the synthetic psilocybin segment held a 38% market share in 2025 and is expected to grow at 17.3% CAGR in the market during the forecast period.

Industry Coverage

What are U.S. Psychedelic Mushroom Products?

Psychedelic mushroom products are products developed from psychoactive compounds. They have active compounds like psilocybin, beta-carbolines, psilocin, non-psilocybin varieties, and secondary alkaloids. They help in addiction recovery, physical pain management, mental health treatment, spiritual growth, subtle mood lifts, and personality changes. Diverse products include edibles, capsules, whole mushrooms, teas, grow kits, chocolates, and powders. Psychedelic mushroom products are widely used for spiritual, recreational, and therapeutic applications. 

The U.S. psychedelic mushroom products industry growth is driven by the growing legalization, rising treatments for mental health, increasing mainstream acceptance, growing commercialization, increased product diversity, increasing rates of PTSD, surging media influence, strong institutional support, and growing investment in psychedelic startups.

What are the Key Trends in the U.S. Psychedelic Mushroom Products Market?

• Growing Processed Products Demand:- The surging recreational industry and the transition towards holistic health increase demand for processed products like extracts, jellies, and others. The ease of consumption and standardized dosing help with expansion. 
• Rise in Functional Wellness:- The shift to natural health solutions and the strong focus on stress resilience increases demand for psychedelic mushroom products. The development of innovative formulations helps in boosting functional wellness.
• Growing Therapeutic Demand:- The increased success rate of clinical trials and the rising number of people suffering from mental health issues increase demand for psychedelic mushroom products due to their high efficacy and rapid effects.
• Surging Microdosing:- The huge demand for cognitive enhancers in modern lifestyles and the focus on alleviating symptoms of mental health disorders increase the adoption of microdosing. The ongoing development of consumer-friendly products increases the adoption of microdosing. 

Key Technological Shifts in the U.S. Psychedelic Mushroom Products Market 

The U.S. psychedelic mushroom products industry is undergoing key technological changes driven by demand for clinical validation, selective cultivation, consistency, and standardization. Advancements like robotics, synthetic biology, automated vertical farming, machine learning, and genetic engineering help in high-throughput production and increasing yield. The artificial intelligence (AI) integration is facilitated by the demand for personalizing experiences and enhancing product safety. 

AI discovers new psychoactive molecules and optimizes the cultivation conditions. AI analyzes the best dosing for consumers and easily adjusts environmental factors. It predicts the best harvest time and lowers the R&D time. It assesses toxicity, analyzes minor discolorations, and enhances harvest yield. It also tracks patient mood and verifies product purity. Overall, AI helps in compound discovery and the development of customized treatment.

Trade Analysis of the U.S. Psychedelic Mushroom Products Market: Import & Export Statistics

• The United States exported $163K of processed mushrooms in February 2026. (Source:- oec.world)
• The United States imported $9.18M of processed mushrooms in February 2026. (Source:- oec.world)
• The United States exported $1.67M of processed mushrooms in 2025. (Source:- oec.world)
• The United States imported $131M of processed mushrooms in 2025. (Source:- oec.world)
• From March 2025 to February 2026, the United States exported $1.85M of processed mushrooms. 

Supply Chain Analysis of the U.S. Psychedelic Mushroom Products Market 

Raw Material Procurement

• The stage acquires raw materials like alder wood chips, oats, straw, rice bran, corn molasses, casing layer, deciduous wood pellets, white millets, corn cobs, wheat bran, and cottonseed meal.
• Key Players:- PNW Spore Co., Azoth Biotech, Monterey Nutra, Compass Pathways, Planet Mushroom, Atai Life Sciences, Enveric Biosciences

Processing and Preservation

• Processing involves steps, such as drying mushrooms, grinding, extraction, selection of solvent, purification, standardization of concentrated extract, and drying. Preservation includes methods like freeze-drying, cold storage, drying, and vacuum packaging. 
• Key Players:- MYYCO, Usona Institute, Spiritus Oregon, Core One Labs, Compass Pathways

Quality Testing and Certifications

• Quality testing focuses on the evaluation of qualities like active compounds, stability assessment, microbial analysis, pesticide screening, homogeneity check, heavy metal screening, residual solvent testing, and microscopic analysis. Certifications like FDA and cGMP are required. 
• Key Players:- Tentamus Group, Oregon Psilocybin Services, Alkemist Labs, Orange Photonics, Lightlab3

U.S. Psychedelic Mushroom Products Market Segmental Insights 

Product Type Insights

The Psilocybin-Infused Products Segment Dominated the Market with 38% of Market Share in 2025

The psilocybin-infused products segment dominated the U.S. psychedelic mushroom products market with a 38% share in 2025 due to the consumer preference for palatable formats. The strong consumer focus on mental health and the need to address addiction increases demand for psilocybin-infused products. The increased interest in holistic mental wellness and the changing societal attitudes increase the adoption of psilocybin-infused products. The rise in dried mushrooms drives the segment growth. 

The microdosing products segment held the second-largest market share of 22% in 2025 and is expected to grow at the fastest CAGR of 18.9% during the forecast period due to the adoption of microdosing by professionals. The focus on increasing energy and managing mental wellness increases demand for microdosing products. The mainstream normalization and performance enhancement of microdosing products support segment growth.

The psilocybin mushrooms segment held the third-largest market share of 18% in 2025 due to the growing consumption among experienced users. The development of new solutions for mental health and the expansion of clinical-grade cultivation increase the adoption of psilocybin mushrooms. The cultural acceptance and medicinal potential of psilocybin mushrooms boost segment growth.

The psilocybin extracts segment held the fourth-largest market share of 12% in 2025 due to its higher potency. The focus on treating anxiety and the popularity of pharmaceutical-grade dosing increase the adoption of psilocybin extracts. The nutraceutical trends and the expansion of clinical settings increase the adoption of psilocybin extracts. The advanced extraction techniques and the increased research drive the market growth.  

Application Insights

The Mental Health Treatment Segment Led the Market with 44% of Market Share in 2025

The mental health treatment segment led the U.S. psychedelic mushroom products market with a 44% share in 2025 and is expected to grow at the fastest CAGR of 17.8% during the forecast period due to the increased demand for PTSD treatment. The growing mental health conditions and the need for holistic alternatives increase the adoption of psychedelic mushroom products. The growing burden of mental health and the shift to psychedelic-assisted therapy drive segment growth.

The recreational use segment held the second-largest market share of 26% in 2025 due to the rising cultural acceptance. The strong focus on personal growth and the low addiction potential increase demand for psychedelic mushroom products. The development of processed products and the focus on personal healing increase the adoption of psychedelic mushroom products. The increased experimentation in younger demographics supports segment growth.  

The cognitive enhancement segment held the third-largest market share of 18% in 2025 due to the availability of creativity enhancement tools. The focus on improving cognitive function and enhancing synaptic density increases demand for psychedelic mushroom products. The popularity of natural nootropics and the focus on brain fog relief increase the adoption of psychedelic mushroom products. The increased use of non-stimulant alternatives boosts segment growth.   

The spiritual & wellness use segment held the fourth-largest market share of 12% in 2025 due to the interest in mindfulness. The trend of self-optimization and the expansion of wellness retreats increases demand for psychedelic mushroom products. The focus on improving mental clarity and expanding retreat centers increases the adoption of psychedelic mushroom products. The rise in wellness tourism supports segment growth.

Distribution Channel Insights

The Online Retail Segment Held the Largest Market Share of 36% in 2025

The online retail segment held the largest revenue share of 36% in the U.S. psychedelic mushroom products market in 2025 and is expected to grow at the fastest CAGR of 18.2% during the forecast period due to the increased availability of subscription-based microdosing kits. The preference for maintaining privacy and the availability of processed mushrooms increase the adoption of online retail. The rise in digital-native consumers and discreet shipping in online retail drives the segment growth.   

The specialty stores segment held the second-largest market share of 28% in 2025 due to the expansion of legal dispensaries in regulated regions. The demand for curated experiences and consumer focus on understanding dosing increases the adoption of specialty stores. The expansion of pre-dosed products and product quality control increases the adoption of specialty stores, supporting the segment growth.

The clinics & therapeutic centers segment held the third-largest market share of 22% in 2025 due to the availability of insurance coverage. The focus on controlled administration and the need to maximize therapeutic potential increases the adoption of clinics & therapeutic centers. The availability of medical supervision and promising clinical evidence boost segment growth.  

The underground/informal channels segment held the fourth-largest market share of 14% in 2025 due to the presence of cost-sensitive consumers. The growing scientific evidence and the medicalization barriers increase the adoption of underground/informal channels. The microdosing demand and the growth in online gray markets support segment growth.  

End User Insights

The Adults (25-45 Years) Segment Contributed the Biggest Market Share of 42% in 2025

The adults (25-45 years) segment contributed the biggest revenue share of 42% in the U.S. psychedelic mushroom products market in 2025 due to the increased stress levels. Adults' preference for self-treating and the growing number of health-conscious adults increase demand for psilocybin-infused products. The popularity of microdosing among tech professionals and the strong preference for small-processed options drive the segment growth.  

The clinical patients segment held the second-largest market share of 26% in 2025 and is expected to grow at the fastest CAGR of 18.5% during the forecast period due to the growth in prescription-based therapy. The focus on treating nicotine dependency and the priority to plant-based remedies increases the adoption of psychedelic mushroom products. Increased acceptance by healthcare providers supports segment growth.

The older adults (45+ years) segment held the third-largest market share of 18% in 2025 due to the interest in cognitive longevity. The growing rate of late-life depression and the rise in treatment-resistant conditions increase demand for psychedelic mushroom products. The strong focus on life enhancement and the growing awareness of the anxiety boost segment growth.

The young adults (18-24 years) segment held the fourth-largest market share of 14% in 2025 due to the growing social media influence. The higher depression rates and the focus on cognitive enhancement in young adults increase demand for psychedelic mushroom products. Growing experimentation and the increased awareness of mental health crises boost segment growth.

Dosage Type Insights

The Microdose Segment Dominated the Market with 46% of Market Share in 2025

The microdose segment dominated the U.S. psychedelic mushroom products market with a 46% share in 2025 and is expected to grow at the fastest CAGR of 18.6% during the forecast period due to its minimal side effects. The strong focus on enhancing mood and the focus on the enhancement of a functional lifestyle increase demand for microdosing. The sub-perceptual benefits, manageability, and convenience of microdose drives segment growth.   

The standard dose segment held the second-largest market share of 34% in 2025 due to its growing use in therapeutic and recreational applications. The need to lower adverse psychological events and focus on treatment-resistant depression increases the adoption of the standard dose. Consumer familiarity, rising potency, and mainstream acceptance of standard doses support the overall segment growth.     

The high dose (therapeutic) segment held the third-largest market share of 20% in 2025 due to the increased use in clinical therapies. Growing public confidence and the high preference for microdosing increase the adoption of high doses. The treatment of severe PTSD and the safety of guided treatments increase the adoption of high doses. The rise in certified therapy centers boosts segment growth.

Source Insights

The Natural Mushrooms Segment Held a Dominant Market Share of 62% in 2025

The natural mushrooms segment held a dominant revenue share of 62% in the U.S. psychedelic mushroom products market in 2025 due to the increasing use of organic mushrooms. The simplified production, perceived purity, ease of cultivation, and widespread accessibility of natural mushrooms help with market expansion. The growing microdosing trend and the DIY growing kits increase the adoption of natural mushrooms, driving the overall segment growth. 

The synthetic psilocybin segment held the second-largest market share of 38% in 2025 and is expected to grow at the fastest CAGR of 17.3% during the forecast period due to its pharmaceutical-grade consistency. The increased use of synthetic psilocybin in mental health applications helps with expansion. Regulatory approval, reliability, process efficiency, and pharmaceutical scalability of synthetic psilocybin support the segment growth.

Recent Developments 

Quirky Monkey

• In September 2025, Quirky Monkey launched two indulgent mushroom hot chocolates. The range includes Simply the Zest and Sweet N Salty. The range made without added sweeteners. The range manufactures using ingredients like lion’s mane, cordyceps, premium raw cacao, cordyceps, and superfood ingredients.  (Source:- Organic-Business)

Mycopreneur

• In February 2025, Mycopreneur launched functional mushroom chocolate, Mycoday. The chocolate is made up of four mushroom species and contains cordyceps, chaga, reishi, & lion’s mane. The chocolate supports cholesterol management and enhances immune health. (Source:- Nutraceuticalbusinessreview)

Top Companies in the U.S. Psychedelic Mushroom Products Market 

• Shroomland:- The company manufactures various mushroom products like edibles, psilocybin microdose capsules, dried mushrooms, cannabis, and tea. 
• Compass Pathways:- The British biotechnology company produces COMP360 for treating various conditions like anorexia, depression, and PTSD. 
• Atai Life Sciences:- The biopharmaceutical company manufactures psychedelic products like EMP-01, BPL-003, and VLS-01 for mental health disorders. 
• MindMed:- The biopharmaceutical company manufactures psychedelic-based medicines for brain health disorders.  
• Enveric Biosciences:- The biotechnology company manufactures Next-Gen Psychedelics, EB-003, EVM201 series for treating addiction, depression, and anxiety. 

Other Companies

• Blissmushrooms
• Numinus Wellness
• oneupmushroomsbar.com
• Gilgamesh Pharmaceuticals
• Psilocybin Lounge
• Perception Neuroscience
• MycoMeditations
• Terran Biosciences

Segments Covered in the Report

By Product Type

• Psilocybin Mushrooms 
  
  • Whole Mushrooms
  • Dried Mushrooms
  • Powdered Mushrooms
• Psilocybin Extracts 
  
  • Liquid Extracts
  • Resin/Concentrates
• Psilocybin-infused Products 
  
  • Edibles 
    
    • Chocolates
    • Gummies
    • Beverages
  • Capsules & Tablets
  • Tinctures
• Microdosing Products 
  
  • Pre-measured Capsules
  • Microdose Strips
• Functional Blends (Psychedelic + Adaptogens) 
  
  • Mushroom Blends with Lion’s Mane
  • Mushroom Blends with Ashwagandha

By Application

• Mental Health Treatment 
  
  • Depression
  • Anxiety Disorders
  • PTSD
  • Addiction Treatment
• Cognitive Enhancement 
  
  • Focus & Productivity
  • Creativity Enhancement
• Recreational Use
• Spiritual & Wellness Use 
  
  • Meditation Support
  • Consciousness Exploration

By Distribution Channel

• Online Retail 
  
  • Brand-owned Websites
  • E-commerce Platforms
• Specialty Stores 
  
  • Wellness Stores
  • Psychedelic Dispensaries (legal regions)
• Clinics & Therapeutic Centers
• Underground/Informal Channels

By End User

• Adults (25–45 years)
• Older Adults (45+ years)
• Young Adults (18–24 years)
• Clinical Patients 
  
  • Psychiatric Patients
  • Chronic Illness Patients

By Dosage Type

• Microdose
• Standard Dose
• High Dose (Therapeutic/Guided)

By Source

• Natural Mushrooms 
  
  • Organic Cultivation
  • Wild Harvested
• Synthetic Psilocybin